Extending the use of stiripentol to other epileptic syndromes: A case of PCDH19-related epilepsy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam. PCDH19-related epilepsy is an emerging epileptic syndrome characterized by the occurrence of epilepsy in female patients associated with mental retardation and autistic features in most cases. It shares many features with DS: age of onset, normal development before the onset, fever sensitivity, cognitive impairment during the time, drug-resistance. Basing on the numerous similarities between DS and PCDH19-related epilepsy, we tried stiripentol in a nine and half year old female patient with PCDH19-related resistant epilepsy, as add-on treatment to valproate and clobazam. It had a surprising efficacy as the patient had a two years and ten months seizure free period, as never in her epilepsy history. Up to date, clinical trials of stiripentol have been always focused on DS. The delineation of new epileptic syndromes, as PCDH19-related epilepsy, opens new scenarios to the utilization of this AED. This case report is suggestive of a good response of PCDH19-related Epilepsy to stiripentol. However further cases and above all clinical trials are necessary to confirm this result.

Original languageEnglish
Pages (from-to)248-250
Number of pages3
JournalEuropean Journal of Paediatric Neurology
Volume19
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Epilepsy
Myoclonic Epilepsy
Valproic Acid
Anticonvulsants
Clinical Trials
stiripentol
Age of Onset
Drug Resistance
Intellectual Disability
Seizures
Fever
Therapeutics

Keywords

  • Antiepileptic drugs
  • Dravet syndrome
  • PCDH19-related epilepsy
  • Stiripentol

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{65feb177e94d48ccafc5fc4083e6b2cc,
title = "Extending the use of stiripentol to other epileptic syndromes: A case of PCDH19-related epilepsy",
abstract = "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam. PCDH19-related epilepsy is an emerging epileptic syndrome characterized by the occurrence of epilepsy in female patients associated with mental retardation and autistic features in most cases. It shares many features with DS: age of onset, normal development before the onset, fever sensitivity, cognitive impairment during the time, drug-resistance. Basing on the numerous similarities between DS and PCDH19-related epilepsy, we tried stiripentol in a nine and half year old female patient with PCDH19-related resistant epilepsy, as add-on treatment to valproate and clobazam. It had a surprising efficacy as the patient had a two years and ten months seizure free period, as never in her epilepsy history. Up to date, clinical trials of stiripentol have been always focused on DS. The delineation of new epileptic syndromes, as PCDH19-related epilepsy, opens new scenarios to the utilization of this AED. This case report is suggestive of a good response of PCDH19-related Epilepsy to stiripentol. However further cases and above all clinical trials are necessary to confirm this result.",
keywords = "Antiepileptic drugs, Dravet syndrome, PCDH19-related epilepsy, Stiripentol",
author = "Marina Trivisano and Nicola Specchio and Federico Vigevano",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.ejpn.2014.11.008",
language = "English",
volume = "19",
pages = "248--250",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Extending the use of stiripentol to other epileptic syndromes

T2 - A case of PCDH19-related epilepsy

AU - Trivisano, Marina

AU - Specchio, Nicola

AU - Vigevano, Federico

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam. PCDH19-related epilepsy is an emerging epileptic syndrome characterized by the occurrence of epilepsy in female patients associated with mental retardation and autistic features in most cases. It shares many features with DS: age of onset, normal development before the onset, fever sensitivity, cognitive impairment during the time, drug-resistance. Basing on the numerous similarities between DS and PCDH19-related epilepsy, we tried stiripentol in a nine and half year old female patient with PCDH19-related resistant epilepsy, as add-on treatment to valproate and clobazam. It had a surprising efficacy as the patient had a two years and ten months seizure free period, as never in her epilepsy history. Up to date, clinical trials of stiripentol have been always focused on DS. The delineation of new epileptic syndromes, as PCDH19-related epilepsy, opens new scenarios to the utilization of this AED. This case report is suggestive of a good response of PCDH19-related Epilepsy to stiripentol. However further cases and above all clinical trials are necessary to confirm this result.

AB - Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam. PCDH19-related epilepsy is an emerging epileptic syndrome characterized by the occurrence of epilepsy in female patients associated with mental retardation and autistic features in most cases. It shares many features with DS: age of onset, normal development before the onset, fever sensitivity, cognitive impairment during the time, drug-resistance. Basing on the numerous similarities between DS and PCDH19-related epilepsy, we tried stiripentol in a nine and half year old female patient with PCDH19-related resistant epilepsy, as add-on treatment to valproate and clobazam. It had a surprising efficacy as the patient had a two years and ten months seizure free period, as never in her epilepsy history. Up to date, clinical trials of stiripentol have been always focused on DS. The delineation of new epileptic syndromes, as PCDH19-related epilepsy, opens new scenarios to the utilization of this AED. This case report is suggestive of a good response of PCDH19-related Epilepsy to stiripentol. However further cases and above all clinical trials are necessary to confirm this result.

KW - Antiepileptic drugs

KW - Dravet syndrome

KW - PCDH19-related epilepsy

KW - Stiripentol

UR - http://www.scopus.com/inward/record.url?scp=84923133010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923133010&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2014.11.008

DO - 10.1016/j.ejpn.2014.11.008

M3 - Article

C2 - 25510386

AN - SCOPUS:84923133010

VL - 19

SP - 248

EP - 250

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 2

ER -